Bioresorbable Coronary Scaffolds Market Segmentation:
Drug Type Segment Analysis
Sirolimus and its analogues are leading the segment and are expected to hold the share value of 92% by 2035. This dominance is due to their proven efficacy in suppressing neointimal hyperplasia, which prevents restenosis. Their mechanism of action, which halts the cell cycle, is well-understood and supported by decades of clinical outcomes data from permanent drug-eluting stents. The Centers for Disease Control and Prevention (CDC) recognizes restenosis as a key complication of PCI, making effective antiproliferative drug coating a critical determinant of device adoption and commercial success.
Application Segment Analysis
The coronary artery disease (CAD) segment is poised to capture the largest share in the bioresorbable coronary scaffolds market throughout the assessed timeframe. Its proprietorship is majorly attributed to the predominant occurrence of this CVD type, in comparison to PAD. Its higher rate of severity and mortality is also an influential factor in this segment, which secures a significant portion of the net capital influx from concerned organizations. Testifying to this, the CDC report in October 2024 revealed that approximately 1 in 20 adults with CAD across the U.S. require percutaneous coronary intervention every year. As a result, its clinical priority concentrated more on the total reimbursement for CAD-related BCS procedures in this category, solidifying its position for upcoming years.
End user Segment Analysis
Hospitals are dominating the segment because they are the specialized cardiac facilities that carry out the overwhelming majority of percutaneous coronary interventions (PCIs). They dominate as end-users because they have the requisite catheterization laboratories, special imaging hardware, and very trained interventional cardiologists. The May 2023 NLM study illustrates that the typical cardiac admitting patient has advanced congestive heart failure, at 74% of the study sample, followed by hypertensive heart disease, 48.5%. This concentration of complex cases further reinforces hospitals’ role as the primary setting for adopting advanced devices like bioresorbable coronary scaffolds.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Sub-segments |
|
Material Type |
|
|
Drug Type |
|
|
Application |
|
|
End user |
|
|
Absorption Rate |
|
